Skip to main content
Premium Trial:

Request an Annual Quote

Decode Genetics Gets Another Letter from Nasdaq

NEW YORK (GenomeWeb News) – Decode Genetics has received another letter from the Nasdaq Stock Exchange notifying the firm that for 30 consecutive business days the market value of its publicly traded common stock was below $15 million, which is the minimum level required for continued listing on the Nasdaq Global Market.

Decode, which filed for Chapter 11 bankruptcy protection last month, said Wednesday that Nasdaq informed the firm that it has 90 calendar days to regain compliance. Its shares must have a market value of at least $15 million for 10 consecutive business days in order to meet the exchange's regulations.

Decode received a delisting notice last month from Nasdaq after it filed for bankruptcy protection. The firm said in a filing with the US Securities and Exchange Commission this week that it has appealed the suspension and expects Nasdaq to make a decision on the appeal next month.

Filed under

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.